Vivalis SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Pat Volpe Steps Down As Chairman Of Cardia Bioplastics Ltd
Cardia Bioplastics Ltd announced that Mr. Pat Volpe has stepped down from his role as Chairman of Cardia due to other work commitments. Mr. Richard Tegoni will assume the role of Non-Executive Chairman, effective immediately.
Latest Developments for Valneva SE
- Valneva SE Confirms FY 2013 Revenue Guidance in Line with Analysts' Estimates
- Valneva SE Provides Update on Phase II/III Interim Analysis of Its Pseudomonas Aeruginosa Vaccine Candidate
- Valneva SE Wins FDA Market Exclusivity for the Pediatric Indication of IXIARO in the United States
- Valneva SE Issues FY 2013 Revenue and Grants Guidance
Latest Key Developments in Biotechnology
- PDL BioPharma Inc gives Q4 2013 guidance in line with analysts' estimates
- Lorus Therapeutics Inc completes $7,001,500 prospectus offering of common shares
- KaloBios Pharmaceuticals Inc announces preliminary phase 1 results in advanced hematologic malignancies with kb004, an anti-epha3 monoclonal antibody
- Zogenix Inc announces FDA approval of four mg SUMAVEL DosePro (sumatriptan injection) needle-free delivery system
- Share this
- Digg this